Could TETRALOGIC PHARMACEUTICALS CORP (OTCMKTS:TLOG) Skyrocket? The Stock Had Too Little Sellers

April 16, 2018 - By Bradley Stiles

The stock of TETRALOGIC PHARMACEUTICALS CORP (OTCMKTS:TLOG) registered a decrease of 7.13% in short interest. TLOG’s total short interest was 66,400 shares in April as published by FINRA. Its down 7.13% from 71,500 shares, reported previously. With 107,600 shares average volume, it will take short sellers 1 days to cover their TLOG’s short positions. The short interest to TETRALOGIC PHARMACEUTICALS CORP’s float is 0.45%.

The stock decreased 12.06% or $0.0024 during the last trading session, reaching $0.0175. About 3,338 shares traded. TetraLogic Pharmaceuticals Corporation (OTCMKTS:TLOG) has 0.00% since April 16, 2017 and is . It has underperformed by 11.55% the S&P500.

TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. The company has market cap of $428,139. It has two clinical-stage product candidates in development, such as birinapant and SHAPE. It currently has negative earnings. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases-mimetic, which leads to apoptosis or cell-death in damaged cells.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: